JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1991; 18:1077-1084
© 1991 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bates, E.
Right arrow Articles by Topol, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bates, E.
Right arrow Articles by Topol, E.

Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock

ER Bates and EJ Topol

Department of Internal Medicine, University of Michigan, Ann Arbor.

As many as one quarter of patients treated with thrombolytic therapy present with congestive heart failure or cardiogenic shock. Although thrombolytic therapy has been shown to limit infarct size, preserve left ventricular ejection fraction and decrease mortality in most subgroups of patients, no apparent benefit has been demonstrated in patients with clinical left ventricular dysfunction. The lack of correlation between ejection fraction and other measurements of left ventricular dysfunction such as exercise time, cardiac output, filling pressures, activation of the neurohumoral system and regional perfusion bed abnormalities may partly explain this paradox. Alternatively, lower perfusion rates, higher reocclusion rates, associated mechanical complications or completed infarction may explain these findings. Preliminary data indicate that emergency coronary angioplasty or bypass graft surgery improves survival in selected patients with cardiogenic shock. Because these findings suggest that restoration of infarct artery patency is especially important in patients with clinical left ventricular dysfunction, additional studies are needed in these patients to investigate the potential benefit that new thrombolytic strategies, inotropic or vasodilator agents or intraaortic balloon counterpulsation might offer by augmenting coronary blood flow and improving reperfusion rates. Currently, acute mechanical revascularization should be considered for patients who present with congestive heart failure associated with hypotension or tachycardia and for patients with cardiogenic shock.


This article has been cited by other articles:


Home page
Card Surg AdultHome page
I. George and M. C. Oz
Myocardial Revascularization after Acute Myocardial Infarction
Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696.
[Full Text]


Home page
J Am Coll CardiolHome page
H. C. Wijeysundera, R. Vijayaraghavan, B. K. Nallamothu, J. M. Foody, H. M. Krumholz, C. O. Phillips, A. Kashani, J. J. You, J. V. Tu, and D. T. Ko
Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials
J. Am. Coll. Cardiol., January 30, 2007; 49(4): 422 - 430.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
C. S. Duvernoy and E. R. Bates
Management of Cardiogenic Shock Attributable to Acute Myocardial Infarction in the Reperfusion Era
J Intensive Care Med, July 1, 2005; 20(4): 188 - 198.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. G. Webb, A. M. Lowe, T. A. Sanborn, H. D. White, L. A. Sleeper, R. G. Carere, C. E. Buller, S. C. Wong, J. Boland, V. Dzavik, et al.
Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial
J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1380 - 1386.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
D. C. Lee, W. Ting, and M. C. Oz
Myocardial Revascularization after Acute Myocardial Infarction
Card. Surg. Adult, January 1, 2003; 2(2003): 639 - 658.
[Full Text]


Home page
J Am Coll CardiolHome page
A. H. Wu, L. Parsons, N. R. Every, and E. R. Bates
Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1389 - 1394.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. G. Webb, L. A. Sleeper, C. E. Buller, J. Boland, A. Palazzo, E. Buller, H. D. White, J. S. Hochman, and for the SHOCK Investigators
Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry
J. Am. Coll. Cardiol., September 1, 2000; 36(3_Suppl_A): 1084 - 1090.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Hasdai, R. M. Califf, T. D. Thompson, J. S. Hochman, E. M. Ohman, M. Pfisterer, E. R. Bates, A. Vahanian, P. W. Armstrong, D. A. Criger, et al.
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 136 - 143.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Collins, R. Peto, C. Baigent, and P. Sleight
Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
N. Engl. J. Med., March 20, 1997; 336(12): 847 - 860.
[Full Text] [PDF]


Home page
Med Decis MakingHome page
J. Kellett and J. Clarke
Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction
Med Decis Making, October 1, 1995; 15(4): 297 - 310.
[Abstract] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1991 by the American College of Cardiology Foundation.